• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Aegis Capital reiterated coverage on Kindred Biosciences with a new price target

    1/26/21 9:34:09 AM ET
    $KIN
    Major Pharmaceuticals
    Health Care
    Get the next $KIN alert in real time by email
    Aegis Capital reiterated coverage of Kindred Biosciences with a rating of Buy and set a new price target of $16.00 from $14.00 previously
    Get the next $KIN alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $KIN

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $KIN
    SEC Filings

    View All

    SEC Form 15-12B filed by Kindred Biosciences, Inc.

    15-12B - Kindred Biosciences, Inc. (0001561743) (Filer)

    9/7/21 6:09:47 AM ET
    $KIN
    Major Pharmaceuticals
    Health Care

    SEC Form EFFECT filed by Kindred Biosciences, Inc.

    EFFECT - Kindred Biosciences, Inc. (0001561743) (Filer)

    9/2/21 12:15:28 AM ET
    $KIN
    Major Pharmaceuticals
    Health Care

    SEC Form S-8 POS filed by Kindred Biosciences, Inc.

    S-8 POS - Kindred Biosciences, Inc. (0001561743) (Filer)

    8/30/21 9:21:56 AM ET
    $KIN
    Major Pharmaceuticals
    Health Care

    $KIN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    TCW Special Purpose Acquisition Corp. Appoints Nanxi Liu to Board of Directors

    TCW Special Purpose Acquisition Corp. (NYSE:TSPQ), a $464 million blank check company sponsored by The TCW Group, Inc. ("TCW"), announced that it has appointed Nanxi Liu to the Company's Board of Directors. Since April 2021, Ms. Liu has served on the TCW Special Purpose Acquisition Corporation's Advisory Board. She is the Co-Founder and Co-CEO of Blaze Technology, a no-code platform that enables teams to build web applications and internal tools. Ms. Liu co-founded and served as CEO of Enplug, a leading digital signage software company used by Fortune 500 companies, until it was acquired in 2021. She previously co-founded Nanoly Bioscience, a venture-backed biotech company that develops po

    10/24/22 9:00:00 AM ET
    $ELAN
    $PRTS
    $TSPQ
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Auto & Home Supply Stores
    Consumer Discretionary

    Elanco Announces Agreement to Acquire Kindred Biosciences

    Bolt-on Acquisition Accelerates Elanco's Expansion in Pet Health Elanco to host conference call for investment community at 8:00 am Eastern Time    Elanco will acquire all outstanding stock of Kindred Biosciences at a price of $9.25 per share, or approximately $440 million, a premium of 52% based on the 30-day average. Transaction brings three potential blockbusters in the development phase, complements existing pipeline, and augments monoclonal antibody R&D capabilities. Increasing Investor Day revenue from innovation expectation by $100 million, to $600 million to $700 million by 2025, with significant opportunity beyond the period. Differentiated, disruptive portfolio in ato

    6/16/21 6:30:00 AM ET
    $KIN
    $ELAN
    Major Pharmaceuticals
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Kindred Biosciences Announces Positive Results from Pivotal Efficacy Study of Parvovirus Monoclonal Antibody for the Prevention of Deaths in Dogs Infected by Parvovirus

    SAN FRANCISCO, June 2, 2021 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ:KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced positive results from a pivotal efficacy study of KIND-030 in dogs infected by parvovirus. The primary endpoint was survival and the results showed 100% survival in the treated group versus 43% survival in the placebo group. KIND-030, a monoclonal antibody targeting canine parvovirus (CPV), is partnered with Elanco Animal Health (NYSE:ELAN). In this randomized, blinded, placebo-controlled study, KIND

    6/2/21 8:31:00 AM ET
    $KIN
    $ELAN
    Major Pharmaceuticals
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $KIN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $KIN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Kindred Biosciences downgraded by Lake Street with a new price target

    Lake Street downgraded Kindred Biosciences from Buy to Hold and set a new price target of $9.25 from $12.00 previously

    6/17/21 11:33:29 AM ET
    $KIN
    Major Pharmaceuticals
    Health Care

    Kindred Biosciences downgraded by HC Wainwright & Co. with a new price target

    HC Wainwright & Co. downgraded Kindred Biosciences from Buy to Neutral and set a new price target of $9.25 from $9.00 previously

    6/17/21 6:07:16 AM ET
    $KIN
    Major Pharmaceuticals
    Health Care

    Kindred Biosciences downgraded by Aegis Capital with a new price target

    Aegis Capital downgraded Kindred Biosciences from Buy to Hold and set a new price target of $9.25 from $16.00 previously

    6/16/21 9:21:39 AM ET
    $KIN
    Major Pharmaceuticals
    Health Care

    SEC Form 4 filed by Park West Asset Management Llc

    4 - Kindred Biosciences, Inc. (0001561743) (Issuer)

    9/13/21 4:30:38 PM ET
    $KIN
    Major Pharmaceuticals
    Health Care

    SEC Form 4: Chin Richard returned $15,884,757 worth of Common Stock to the company (1,717,271 units at $9.25), closing all direct ownership in the company

    4 - Kindred Biosciences, Inc. (0001561743) (Issuer)

    8/30/21 9:46:23 PM ET
    $KIN
    Major Pharmaceuticals
    Health Care

    SEC Form 4: Wee Wendy returned $727,170 worth of Common Stock to the company (78,613 units at $9.25), closing all direct ownership in the company

    4 - Kindred Biosciences, Inc. (0001561743) (Issuer)

    8/30/21 6:08:02 PM ET
    $KIN
    Major Pharmaceuticals
    Health Care

    $KIN
    Leadership Updates

    Live Leadership Updates

    View All

    TCW Special Purpose Acquisition Corp. Appoints Nanxi Liu to Board of Directors

    TCW Special Purpose Acquisition Corp. (NYSE:TSPQ), a $464 million blank check company sponsored by The TCW Group, Inc. ("TCW"), announced that it has appointed Nanxi Liu to the Company's Board of Directors. Since April 2021, Ms. Liu has served on the TCW Special Purpose Acquisition Corporation's Advisory Board. She is the Co-Founder and Co-CEO of Blaze Technology, a no-code platform that enables teams to build web applications and internal tools. Ms. Liu co-founded and served as CEO of Enplug, a leading digital signage software company used by Fortune 500 companies, until it was acquired in 2021. She previously co-founded Nanoly Bioscience, a venture-backed biotech company that develops po

    10/24/22 9:00:00 AM ET
    $ELAN
    $PRTS
    $TSPQ
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Auto & Home Supply Stores
    Consumer Discretionary

    TCW Special Purpose Acquisition Corp. Announces Appointment of Nanxi Liu to Advisory Board

    TCW Special Purpose Acquisition Corp. (NYSE:TSPQ), a $464 million blank check company sponsored by The TCW Group, Inc. ("TCW"), announced that it has appointed Nanxi Liu to its Advisory Board, effective April 26, 2021. Ms. Liu is Co-Founder and CEO of Enplug, a leading digital signage software company used by Fortune 500 companies, and was named one of Forbes 30 Under 30 and Fortune's 10 Most Promising Women Entrepreneurs. She also co-founded Nanoly Bioscience, a venture-backed biotech company that develops polymers that eliminate the need of refrigeration for vaccines and therapeutics. Ms. Liu serves on the Board of Directors of CarParts.com (NASDAQ:PRTS), a leading online provider of aut

    4/26/21 8:30:00 AM ET
    $PRTS
    $KIN
    Auto & Home Supply Stores
    Consumer Discretionary
    Major Pharmaceuticals
    Health Care

    $KIN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Kindred Biosciences, Inc. (Amendment)

    SC 13G/A - Kindred Biosciences, Inc. (0001561743) (Subject)

    9/13/21 4:30:56 PM ET
    $KIN
    Major Pharmaceuticals
    Health Care

    SEC Form SC 13D/A filed by Kindred Biosciences, Inc. (Amendment)

    SC 13D/A - Kindred Biosciences, Inc. (0001561743) (Subject)

    8/31/21 4:00:27 PM ET
    $KIN
    Major Pharmaceuticals
    Health Care

    SEC Form SC 13D/A filed by Kindred Biosciences, Inc. (Amendment)

    SC 13D/A - Kindred Biosciences, Inc. (0001561743) (Subject)

    8/5/21 4:24:14 PM ET
    $KIN
    Major Pharmaceuticals
    Health Care